Relief Therapeutics Holding (Relief Therapeutics Holding) Debt-to-Equity

: 0.03 (As of Jun. 2023)

View and export this data going back to 1990. Start your Free Trial

Relief Therapeutics Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.99 Mil. Relief Therapeutics Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $2.61 Mil. Relief Therapeutics Holding's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $104.81 Mil. Relief Therapeutics Holding's debt to equity for the quarter that ended in Jun. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Relief Therapeutics Holding's Debt-to-Equity or its related term are showing as below:

RLFTF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.07 Max: 0.47
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Relief Therapeutics Holding was 0.47. The lowest was 0.02. And the median was 0.07.

RLFTF's Debt-to-Equity is ranked better than
80.97% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs RLFTF: 0.03

Relief Therapeutics Holding Debt-to-Equity Historical Data

The historical data trend for Relief Therapeutics Holding's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.22

0.07

0.02

Relief Therapeutics Holding Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															0.06	0.02	0.02	0.02	0.03

Competitive Comparison

For the Biotechnology subindustry, Relief Therapeutics Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relief Therapeutics Holding Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Debt-to-Equity falls into.

Relief Therapeutics Holding Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Relief Therapeutics Holding's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.876	+	2.413)	/	156.094
	=	0.02

Relief Therapeutics Holding's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.991	+	2.607)	/	104.805
	=	0.03

Relief Therapeutics Holding (OTCPK:RLFTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Relief Therapeutics Holding Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFz:UK RLF:Switzerland

Address

Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.